← DaVita HealthCare Partners overview

DaVita HealthCare Partners vs Guardant Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DaVita HealthCare Partners Inc (DVA)

Q3 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

July 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Latest
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Guardant Health Inc (GH)

Q3 2026
▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

  • UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.

    This is a major new demand catalyst that directly expands the market for Guardant's key screening product.

  • Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.

    This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.

  • Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.

    It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.

July 2026
▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

  • UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.

    This is a major new demand catalyst that directly expands the market for Guardant's key screening product.

  • Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.

    This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.

  • Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.

    It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.

Latest
▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

  • UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.

    This is a major new demand catalyst that directly expands the market for Guardant's key screening product.

  • Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.

    This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.

  • Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.

    It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.

© 2026 MarketIVWhy